JP2023540611A5 - - Google Patents

Info

Publication number
JP2023540611A5
JP2023540611A5 JP2023515803A JP2023515803A JP2023540611A5 JP 2023540611 A5 JP2023540611 A5 JP 2023540611A5 JP 2023515803 A JP2023515803 A JP 2023515803A JP 2023515803 A JP2023515803 A JP 2023515803A JP 2023540611 A5 JP2023540611 A5 JP 2023540611A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540611A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/075005 external-priority patent/WO2022053650A1/en
Publication of JP2023540611A publication Critical patent/JP2023540611A/ja
Publication of JP2023540611A5 publication Critical patent/JP2023540611A5/ja
Pending legal-status Critical Current

Links

JP2023515803A 2020-09-11 2021-09-10 治療用b7-h4結合分子 Pending JP2023540611A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063077207P 2020-09-11 2020-09-11
US63/077,207 2020-09-11
PCT/EP2021/075005 WO2022053650A1 (en) 2020-09-11 2021-09-10 Therapeutic b7-h4 binding molecules

Publications (2)

Publication Number Publication Date
JP2023540611A JP2023540611A (ja) 2023-09-25
JP2023540611A5 true JP2023540611A5 (OSRAM) 2024-09-09

Family

ID=77989768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515803A Pending JP2023540611A (ja) 2020-09-11 2021-09-10 治療用b7-h4結合分子

Country Status (18)

Country Link
US (2) US11795225B2 (OSRAM)
EP (1) EP4211166A1 (OSRAM)
JP (1) JP2023540611A (OSRAM)
KR (1) KR20230084497A (OSRAM)
CN (1) CN116829592A (OSRAM)
AR (1) AR123480A1 (OSRAM)
AU (1) AU2021339953B2 (OSRAM)
BR (1) BR112023004415A2 (OSRAM)
CA (1) CA3193594A1 (OSRAM)
CL (1) CL2023000683A1 (OSRAM)
CO (1) CO2023004379A2 (OSRAM)
CR (1) CR20230146A (OSRAM)
EC (1) ECSP23025680A (OSRAM)
IL (1) IL301041A (OSRAM)
MX (1) MX2023002940A (OSRAM)
SA (1) SA523442921B1 (OSRAM)
TW (1) TW202233670A (OSRAM)
WO (1) WO2022053650A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202140076A (zh) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
CN115160403B (zh) * 2022-07-05 2025-06-27 博石丰生命科技(南通)有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法
EP4309676A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
CA3263276A1 (en) * 2022-07-28 2024-02-01 Medimmune, Llc Polytherapy for the treatment of cancer
AU2023359114A1 (en) 2022-10-09 2025-04-24 LaNova Medicines Limited Compounds, compositions and methods
JP2026506049A (ja) * 2023-02-16 2026-02-20 アストラゼネカ・アクチエボラーグ 治療用結合分子を用いた癌の治療のための併用療法
TW202506194A (zh) * 2023-04-28 2025-02-16 英商梅迪繆思有限公司 用於治療癌症的b7-h4治療性結合分子
WO2025027472A2 (en) * 2023-07-31 2025-02-06 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US776841A (en) 1904-03-16 1904-12-06 Annie L See Piano-action.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3546807C2 (OSRAM) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン,エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
WO2004005326A2 (de) 2002-07-09 2004-01-15 Morphochem Aktiengellschaft Fu Tubulysinkonjugate
DK1523493T3 (da) 2002-07-09 2013-12-02 Alexander Doemling Nye tubulysinanaloge
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
TW200902554A (en) 2007-05-08 2009-01-16 Genentech Inc Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
US8476451B2 (en) 2007-07-20 2013-07-02 The Regents Of The University Of California Tubulysin D analogues
WO2009012958A2 (en) 2007-07-20 2009-01-29 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
AU2008312457B2 (en) 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
WO2009055562A1 (en) 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
MX2013001402A (es) 2010-08-06 2013-08-29 Endocyte Inc Proceso para preparar tubulisinas.
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
WO2015155345A1 (en) 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
UY36075A (es) 2014-04-11 2015-10-30 Medimmune Llc Derivados de tubulisina
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
CN113698488A (zh) * 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
WO2020140070A1 (en) * 2018-12-27 2020-07-02 Gigagen, Inc. Anti-b7-h4 binding proteins and methods of use thereof
CA3189590A1 (en) * 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses

Similar Documents

Publication Publication Date Title
JP7401126B2 (ja) 抗cubドメイン含有タンパク質1(cdcp1)抗体、抗体薬物コンジュゲート、およびその使用方法
ES2657970T3 (es) Anticuerpos contra ROR1 de conejo/ser humano quiméricos
CN110121507B (zh) 抗sez6l2抗体和抗体药物缀合物
JP2018127469A5 (OSRAM)
KR20200027971A (ko) 항-cd166 항체 및 이의 용도
KR20210042120A (ko) 항체-약물 콘주게이트와 튜불린 저해제의 조합
CN113784987B (zh) 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
JP2017535246A5 (OSRAM)
JP2019532056A5 (OSRAM)
AU2016203839A1 (en) Antibody-drug conjugates
JP2014524902A5 (OSRAM)
CN113710271A (zh) 抗cd228抗体和抗体-药物缀合物
JP2022016581A (ja) 抗edb抗体および抗体-薬物コンジュゲート
JP7264831B2 (ja) 抗globo h抗体を含有する抗体-薬物コンジュゲートおよびその使用
US20230167200A1 (en) Platform for constructing multispecific antibody
JP7679380B2 (ja) Cd276に特異的な抗体-薬物コンジュゲートおよびその使用
JP2022512139A (ja) 腫瘍性疾患の治療のためのpd-l1抗体と組み合わせたil-15タンパク質複合体の使用
JP7379347B2 (ja) プレクチン1結合抗体およびその使用
AU2018285523A1 (en) Antibody drug conjugates that bind LGR5
JP2025508380A5 (OSRAM)
US20240358847A1 (en) Trop2 binders and conjugates thereof
CN110141666A (zh) 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
WO2025099152A1 (en) Antibodies and molecular conjugates thereof targeting upar
TW202444431A (zh) 抗體藥物偶聯物在製備預防和/或治療癌症的藥物中的用途
WO2026098621A1 (zh) 工程改造的定点偶联抗体、抗体偶联药物及其应用